This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anscher, M. S. Articles by Jirtle, R. L. Search for Related Content PubMed PubMed Citation Articles by Anscher, M. S. Articles by Jirtle, R. L. Social Bookmarking                            What's this?

Using Plasma Transforming Growth Factor Beta-1 During Radiotherapy to Select Patients for Dose Escalation

From the Departments of Radiation Oncology, Medicine, and Community and Family Medicine, Duke University Medical Center, Durham, NC.

Address reprint requests to Mitchell S. Anscher, MD, Box 3085, Duke University Medical Center, Durham, NC 27710; email: anscher{at}radonc.duke.edu

PURPOSE: The ability to prescribe treatment based on relative risks for normal tissue injury has important implications for oncologists. In non–small-cell lung cancer, increasing the dose of radiation may improve local control and survival. Changes in plasma transforming growth factor beta (TGFß) levels during radiotherapy (RT) may identify patients at low risk for complications in whom higher doses of radiation could be safely delivered.

PATIENT AND METHODS: Patients with locally advanced or medically inoperable non–small-cell lung cancer received three-dimensional conformal RT to the primary tumor and radiographically involved nodes to a dose of 73.6 Gy (1.6 Gy twice daily). If the plasma TGFß level was normal after 73.6 Gy, additional twice daily RT was delivered to successively higher total doses. The maximum-tolerated dose was defined as the highest radiation dose at which one grade 4 (life-threatening) late toxicity and two grade 3 to 4 (severe life-threatening) late toxicities occurred.

RESULTS: Thirty-eight patients were enrolled. Median follow-up was 16 months. Twenty-four patients were not eligible for radiation dose escalation beyond 73.6 Gy because of persistently abnormal TGFß levels. Fourteen patients whose TGFß levels were normal after 73.6 Gy were escalated to 80 Gy (n = 8) and 86.4 Gy (n = 6). In the 86.4-Gy group, dose-limiting toxicity was reached because there were two (33%) grade 3 late toxicities.

CONCLUSION: It is feasible to use plasma TGFß levels to select patients for RT dose escalation for non–small-cell lung cancer. The maximum-tolerated dose using this approach is 86.4 Gy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. M. Bentzen and A. Trotti Evaluation of Early and Late Toxicities in Chemoradiation Trials J. Clin. Oncol., September 10, 2007; 25(26): 4096 - 4103. [Abstract] [Full Text] [PDF]

				C. Tabata, Y. Kadokawa, R. Tabata, M. Takahashi, K. Okoshi, Y. Sakai, M. Mishima, and H. Kubo All-trans-Retinoic Acid Prevents Radiation- or Bleomycin-induced Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., December 15, 2006; 174(12): 1352 - 1360. [Abstract] [Full Text] [PDF]

				C. Tabata, H. Kubo, R. Tabata, M. Wada, K. Sakuma, M. Ichikawa, S. Fujita, T. Mio, and M. Mishima All-trans retinoic acid modulates radiation-induced proliferation of lung fibroblasts via IL-6/IL-6R system Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L597 - L606. [Abstract] [Full Text] [PDF]

				R. L. Elliott and G. C. Blobe Role of Transforming Growth Factor Beta in Human Cancer J. Clin. Oncol., March 20, 2005; 23(9): 2078 - 2093. [Abstract] [Full Text] [PDF]

				L. B. Marks, J. Garst, M. A. Socinski, G. Sibley, A. W. Blackstock, J. E. H. S. Zhou, T. Shafman, A. Tisch, R. Clough, X. Yu, et al. Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium J. Clin. Oncol., November 1, 2004; 22(21): 4329 - 4340. [Abstract] [Full Text] [PDF]

				C. N. Coleman Linking Radiation Oncology and Imaging through Molecular Biology (or Now That Therapy and Diagnosis Have Separated, It's Time to Get Together Again!) Radiology, July 1, 2003; 228(1): 29 - 35. [Abstract] [Full Text] [PDF]